A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

被引：3

作者：

Krebs, M. ^{[1
,2
]}

Brunsvig, P. ^{[3
]}

Helland, A. ^{[4
]}

Vinolas, N. ^{[5
]}

Aix, S. ^{[6
]}

Carcereny, E. ^{[7
,8
,9
]}

Domine Gomez, M. ^{[10
]}

Trigo Perez, J. M. ^{[11
]}

Arriola, E. ^{[12
]}

Garcia Campelo, R. ^{[13
]}

Spicer, J. ^{[14
]}

Thompson, J. ^{[15
]}

Ortega Granados, A. L. ^{[16
]}

Holt, R. ^{[17
]}

Smethurst, D. ^{[17
]}

Lorens, J. ^{[17
]}

Shoaib, M. ^{[17
]}

Siddiqui, A. ^{[17
]}

Schoelermann, J. ^{[17
]}

Lorens, K. ^{[17
]}

Schmidt, E. ^{[18
]}

Chisamore, M. J. ^{[19
]}

Felip, E. ^{[20
]}

机构：

[1] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[2] Univ Manchester, Manchester, Lancs, England

[3] Oslo Univ Hosp, Oslo, Norway

[4] Oslo Univ Hosp, Inst Canc Res, Norwegian Radium Hosp, Oslo, Norway

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Hosp 12 Octubre Carretera Andalucia, Madrid, Spain

[7] Catalan Inst Oncol Badalona, Med Oncol, Badalona, Spain

[8] Hosp Badalona Germans Trias & Pujol, Badalona, Spain

[9] B Argo, Badalona, Spain

[10] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[11] Hosp Virgen de La Victoria, Malaga, Spain

[12] Hosp Mar, Oncol, Barcelona, Spain

[13] Univ Hosp A Coruna Xxiac Sergas, Med Oncol Serv, La Coruna, Spain

[14] KingS Coll London, Guys Hosp, London, England

[15] Med Coll Wisconsin, Affiliated Hosp, Menomonee Falls, WI USA

[16] Complejo Hosp Jaen, Med Oncol, Jaen, Spain

[17] Bergenbio Asa, Bergen, Norway

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] Merck & Co Inc, Rahway, NJ 07065 USA

[20] Vall DHebron Univ Hosp, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

bemcentinib; AXL; Pembrolizumab;

D O I：

10.1016/j.jtho.2019.08.787

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-72

引用

页码：S388 / S388

页数：1